U.S. stock night market volatility: After the failure and sharp drop of SION-719, SION rebounded 10% in the night market

U.S. Stock Night Market Movements

Sionna Therapeutics rose 10.24% in the night market. Based on recent key news:

1. On August 10, Sionna Therapeutics announced that its cystic fibrosis drug SION-719 failed to meet the primary endpoint in a Phase II clinical trial, causing the stock price to plummet by 92%. The drug did not improve sweat chloride levels, affecting CFTR protein function. The company stated it would halt the development of the drug as an adjunct therapy and review the confounding factors of the trial.

2. On August 11, Vertex Pharmaceuticals' stock surged significantly due to Sionna Therapeutics' drug trial failure, which alleviated ongoing pressure on Vertex. Analysts believe this outcome is a "clearing event" for Vertex, further driving up its stock price.

3. On August 12, Sionna Therapeutics announced that its SION-451 combination therapy Phase I study achieved safety and drug exposure targets. The company is evaluating next steps and stated it would take measures to preserve capital. The cystic fibrosis drug market is highly competitive and carries significant risks.

Stocks with High Trading Volume in the Industry

Twist Bioscience fell 0.03% in the night market. Based on recent key news:

1. On August 11, Twist Bioscience made progress in AI-related revenue. The company began to disclose AI-related revenue separately, allowing institutions to value it more directly, prompting a reassessment of its high-growth business in the market.

2. On August 12, Twist Bioscience approached breakeven. The company has achieved growth for 14 consecutive quarters, and the market holds an optimistic view of its potential in the AI biotechnology sector, driving stock price fluctuations.

3. On August 10, improvements in the efficiency of AI drug design may affect demand. If the efficiency gains in candidate generation and other aspects of AI drug design fall short of expectations, it may impact the release of demand in the related industry chain, leading to stock price fluctuations. The growth potential in the AI biotechnology sector is significant.

Replimune fell 1.97% in the night market. Based on recent key news:

1. On August 10, Replimune announced an underwritten offering at a price of $12.06 per share, expecting to raise approximately $150 million. Following this announcement, the stock price rose by 11.18%.

2. On August 11, Replimune's stock rose 15% in Nasdaq trading to $13.81, as the company announced that the net proceeds from the underwritten offering are expected to be approximately $140.5 million.

3. On August 11, Replimune's stock rose 14.5% to $13.82 due to FDA approval of its skin cancer drug Tudriqev The biotechnology industry has recently performed strongly, with significant capital inflows.

Cullinan Therapeutics rose 6.33% in after-hours trading. Based on recent key news:

1. On August 12, Cullinan Therapeutics released an important announcement via Business Wire regarding its research progress in the field of non-small cell lung cancer. This announcement attracted market attention and drove the stock price up.

2. On August 12, Taiho Oncology issued a statement in collaboration with Cullinan Therapeutics, further boosting investor confidence and leading to a rise in stock price.

3. On August 13, the market reacted positively to the research results on EGFR exon 20 insertion mutations, with Cullinan Therapeutics' related research being considered potentially groundbreaking, stimulating a rise in stock price. The biotechnology industry has recently performed strongly, with significant capital inflows